The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer.
 
Fei Ma
Research Funding - Shanghai Escugen Biotechnology
 
Xiaoxiang Guan
No Relationships to Disclose
 
Jingfen Wang
No Relationships to Disclose
 
Herui Yao
No Relationships to Disclose
 
Xian Wang
No Relationships to Disclose
 
Erika P. Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Yehui Shi
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Nong Xu
Research Funding - MSD (Inst)
 
Huoling Tang
Employment - Bliss Biopharmaceutical
 
Xiangzhu Tian
Employment - Bliss Biopharmaceutical
 
Yuhong Zhou
Employment - Bliss Biopharmaceutical
Leadership - Bliss Biopharmaceutical
Stock and Other Ownership Interests - Bliss Biopharmaceutical
 
Ziping Wei
Employment - Bliss Biopharmaceutical
Leadership - Bliss Biopharmaceutical
Stock and Other Ownership Interests - Bliss Biopharmaceutical
Speakers' Bureau - Bliss Biopharmaceutical
Research Funding - Bliss Biopharmaceutical
Patents, Royalties, Other Intellectual Property - Bliss Biopharmaceutical Co, Ltd
Travel, Accommodations, Expenses - Bliss Biopharmaceutical
 
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI